TOPIC
 / company

Wuxi AppTec

The latest action plan by Shanghai’s municipal government is expected to help local biopharmaceutical firms go global. Photo: Shutterstock

Shanghai to back local biopharma firms’ overseas push, regulatory compliance

The initiative aims to generate about US$7 billion from medical product exports by 2027.

videocam

WuXi AppTec, WuXi Biologics rise in Hong Kong as some operations go up for sale

Senior US official lauds China cooperation on tech-transfer controls

videocam
6

‘China week’ at US House puts biotech firms, Hong Kong offices in cross hairs

Most of the scheduled 28 items have bipartisan support and follow efforts to tackle national and economic security threats posed by Beijing.

videocam
19
Various pieces of US legislation intended to blunt China’s influence and competitive edge are soon due for consideration in Washington. Photo: Shutterstock

US clinical trials in China draw questions on IP theft, Uygur involvement

American drug companies have collaborated with Chinese military-run hospitals to conduct hundreds of such trials, US lawmakers say.

Hong Kong stocks slip on weak Chinese corporate earnings

WuXi AppTech, WuXi Biologics and Xpeng weighed on the market as fourth-quarter earnings of Chinese companies trail those of peers in the rest of Asia, according to Goldman Sachs.

Advertisement
Advertisement

Time to ‘cut off’ US outbound investment in China biotech firms: House panel

Bipartisan support on show amid concern ‘every bit of value flowing’ to companies in the industry ‘will be used to strengthen the CCP and the PLA’.

videocam
20
Covid-19 testing in an inflatable lab provided by Chinese biotech firm, BGI Genomics, a subsidiary of BGI Group, in Beijing in 2020. US lawmakers have raised alarm over such companies’ reach in the American market. Photo: Xinhua via AP

Chinese biotech firm Wuxi should be sanctioned, US lawmakers urge

In a letter dated February 12, the lawmakers told Treasury Secretary Janet Yellen, Defence Secretary Lloyd Austin and Commerce Secretary Gina Raimondo that the global pharmaceutical giant’s links to China’s Communist Party and military threatened US national security.

videocam
9

Li Auto and WuXi Apptec to join Hong Kong’s Hang Seng Index in December

Chinese electric-car maker Li Auto and pharmaceutical company WuXi Apptec will join the Hang Seng Index as new constituents next month, according to the latest quarterly review by Hong Kong’s index compiler.

AI drug firm Insilico could boost Hong Kong drug discovery sector. Here’s how

Insilico Medicine, a Hong Kong-based artificial intelligence (AI) biotechnology company, hopes to add momentum to the city’s health technology industry with the development of its AI-discovered drug.

videocam
The global AI drug discovery market is expected to grow at a compound annual growth rate of about 34 per cent to US$5.6 billion by 2029 from last year, according to Polaris Market Research. Photo: Shutterstock Images

China’s leading biotech research firm focused on US acquisitions

Wuxi AppTec’s executives say they will fully comply with stringent US requirements as they pursue deals in life sciences and biotech.

(From left): Wuxi AppTec board secretary Chi Yao, chairman Li Ge and CFO Edward Hu, at the company’s press conference to announce its Hong Kong IPO, on Friday. Photo: Edward Wong

With Shanghai listing done, Chinese biotech firm readies Hong Kong IPO

Wuxi AppTec tells Chinese investors to go slow as its stock surges

Shares of the medical researcher, which listed in Shanghai this month after delisting from New York in 2015, have surged almost five-fold from its IPO price

China fast tracks biotech firm’s IPO in race as Asia’s fundraising hub

Mainland’s leading biotech firm privatised in New York two years ago, but has been fast-tracked towards the A-share market just seven weeks after applying to list

Wuxi AppTec’s listing is expected to raise more than 5.7 billion yuan (US$907 million), which will be used to expand its research facilities and build new plants. Photo: Shutterstock
Wuxi AppTec
Wuxi AppTec is Asia's largest provider of contract pharmaceutical research, helping drug makers shorten their discovery and development procedures. Its platform is used by more than 6,000 customers, including biotech and pharmaceutical companies, research institutions, researchers, scientists and entrepreneurs in more than 30 countries. The company was founded by Ge Li, who also chairs Wuxi Biologics.
Chairman / President
Li Ge
CEO / Managing Director
Chen Minzhang
CFO / Finance Director
Shi Ming
Industry
Biopharmaceutical
Website
wuxiapptec.com
Headquarters address
288 Fute Zhong Road Waigaoqiao Free Trade Zone, Pudong New Area, Shanghai, China
Stock Code
SEHK:603259
SSE:603259
Year founded
2000
last updated:
30 September, 2024
Advertisement
Advertisement